Deerfield Management Company, L.P. (Series C) Mereo Biopharma Group PLC Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 6,710,429 shares of MREO stock, worth $23.7 Million. This represents 0.51% of its overall portfolio holdings.
Number of Shares
6,710,429
Previous 6,710,429
-0.0%
Holding current value
$23.7 Million
Previous $24.2 Million
14.17%
% of portfolio
0.51%
Previous 0.51%
Shares
1 transactions
Others Institutions Holding MREO
# of Institutions
85Shares Held
107MCall Options Held
209KPut Options Held
479K-
Rubric Capital Management LP New York, NY15.3MShares$54 Million1.75% of portfolio
-
Janus Henderson Group PLC London, X012.3MShares$43.6 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.72MShares$34.3 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.53MShares$33.7 Million1.33% of portfolio
-
Mangrove Partners New York, NY8.73MShares$30.8 Million4.66% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $441M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...